- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Atezolizumab-induced Guillain–Barré syndrome-like acute demyelinating polyneuropathy responsive to steroid therapy: a case report
-
- M.D. Yamanaka Nanami
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine
-
- M.D., Ph.D. Oishi Mariko
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine
-
- M.D., Ph.D. Shimizu Fumitaka
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine
-
- M.D., Ph.D. Koga Michiaki
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine
-
- M.D., Ph.D. Kanda Takashi
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine
Bibliographic Information
- Other Title
-
- アテゾリズマブ誘発性にギラン・バレー症候群様の急性脱髄性末梢神経障害を呈し，ステロイド併用により軽快した76歳男性例
Search this article
Description
<p>A 76-year-old man, who received atezolizumab for the treatment for small cell lung cancer, acutely developed limb weakness with sensory disturbance after the third course of the treatment. Nerve conduction studies were consistent with demyelinating polyneuropathy and acute demyelinating polyneuropathy caused by atezolizumab was suggested. Atezolizumab was immediately withdrawn, and intravenous immunoglobulin (IVIg) and methylprednisolone pulse therapies with subsequent oral administration of prednisolone were initiated, after which neurological deficits steadily improved. Although Guillain–Barré syndrome-like neuropathy caused by immune checkpoint inhibitor (ICI) was occasionally reported, this is the first case of acute demyelinating polyneuropathy triggered by atezolizumab, monoclonal antibody targeting programmed death-ligand 1. This case suggests that combined treatments with IVIg and corticosteroids are effective for neuropathy induced by atezolizumab as same as those by other ICI.</p>
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 61 (10), 653-657, 2021
Societas Neurologica Japonica